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ABSTRACT
Pharmacokinetic/pharmacodynamic modeling was used to
characterize the antipyretic and anti-inflammatory effects of
naproxen in rats. An indirect response model was used to
describe the antipyretic effects of naproxen after short intrave-
nous infusions. The model assumes that basal temperature (Ta)
is maintained by the balance of fever mediators given by a
constant (zero order) rate of synthesis (Ksyn), and a first order
rate of degradation (Kout). After an intraperitoneal injection of
lipopolysaccharide, the change in Ta was modeled assuming an
increase in fever mediators described as an input rate function
[IR(t)] estimated nonparametrically. An inhibitory Emax model
adequately described the inhibition of IR(t) by naproxen. A more
complex model was used to describe the anti-inflammatory
response of oral naproxen in the carrageenin-induced edema
model. Before carrageenin injection, physiological conditions
are maintained by a balance of inflammation mediators given
by Ksyn and Kout (see above). After carrageenin injection, the
additional synthesis of mediators is described by IR(t) (see
above). Such mediators induced an inflammatory process,
which is governed by a first order rate constant (KIN) that can be
inhibited by the presence of naproxen in plasma. The sigmoidal
Emax model also well described the inhibition of KIN by
naproxen. Estimates for IC50 [concentration of naproxen in
plasma eliciting half of maximum inhibition of IR(t) or KIN] were
4.24 and 4.13 mg/ml, for the antipyretic and anti-inflammatory
effects, respectively.
As other nonsteroidal anti-inflammatory drugs (NSAIDs),
naproxen has been extensively used during the past decades
in the treatment of rheumatoid arthritis, febrile syndrome,
and pain (Davies and Anderson, 1997). Naproxen inhibits
both cyclooxygenase 1 (COX-1; constitutive) and cyclooxygen-
ase 2 (COX-2; induced in settings of inflammation) and
thereby the synthesis of prostaglandins (PGs) and thrombox-
anes (Vane, 1971; Ehrich et al., 1999; Langenbach et al.,
1999).
Limited insight on the in vivo pharmacodynamic (pd) prop-
erties of NSAIDs, based on plasma/biophase levels and drug
effect relationships, have been published. Recently, clinical
protocols characterizing the antipyretic effects of ibuprofen
in children related to biophase concentration (Kelley et al.,
1992; Brown et al., 1998) or to plasma concentration by an
indirect response model (Garg and Jusko, 1994; Troco´niz et
al., 2000), have been proposed. Preclinical studies are useful
alternatives to investigate different pharmacokinetic/phar-
macodynamic (pk/pd) models to get insight into the “in vivo”
mechanism of drug action. To our knowledge pk/pd modeling
of the antipyretic effects of NSAIDs has not been performed
in experimental models. Moreover, only few studies dealing
with the time description of the anti-inflammatory effects of
these agents (Castan˜eda-Herna´ndez et al., 1995; Landoni
and Lees, 1996; Landoni et al., 1999) have been published.
The injection of a wide range of doses of lipopolysaccharide
(lps) into animals induces fever (Kluger, 1991; Yirmiya et al.,
1994; Wachulec et al., 1997). It is known that lps-induced
fever is driven by enhanced formation of cytokines such as
interleukin-1b, interleukin-6, interferons a and b, and tumor
necrosis factor-a. The cytokines increase the synthesis of
PGE2 in circumventricular organs and near to the preoptic
hypothalamic area. There PGE2, via cyclic AMP increasing,
triggers the hypothalamus to elevate body temperature (Ta).
NSAIDs suppress this response by inhibiting the synthesis of
PGE2 (Ruwe et al., 1985; Oka et al., 1997; Zhang et al., 1997).
On the other hand, a time-dependent inflammatory reac-
tion is observed following diverse doses of carrageenin in-
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jected to the paw of rats (Di Rosa et al., 1971; Castan˜eda-
Herna´ndez et al., 1995). In this model, COX-2 levels are
elevated with a concomitant increase in prostaglandin pro-
duction. Although these mediators do not appear to have
direct effects on vascular permeability, both PGE2 and PGI2
markedly enhance edema formation and leukocyte infiltra-
tion by promoting blood flow in the inflamed region. Systemic
inhibition of COX leads to a decreased production of PGs at
sites of inflammation, and in the spinal cord (Coderre et al.,
1990; Seibert et al., 1994). Vane and Botting (1994) sug-
gested that PGs play an important role in promoting the
signs and symptoms of inflammation. Nonetheless, as in the
case of antipyretic effect of naproxen, the kinetics of its
anti-inflammatory action is yet to be characterized.
Therefore, the goal of the current study was to develop a
suitable pk/pd model for the antipyretic and anti-inflamma-
tory effects of naproxen. To estimate its pd properties, exper-
imentally induced pyresis or inflammation models were re-
quired. Thus, baseline variations within the time span of the
experiments, as occurs with the adjuvant-induced alter-
ations, represent an additional complexity, which should be
included into the models.
Materials and Methods
This work includes results from the pk/pd modeling of the antipy-
retic (study I) and anti-inflammatory (study II) effects of naproxen in
the rat.
Chemicals
The (S)-6-methoxy-a-methyl-2-naphthaleneacetic acid (naproxen)
was supplied by Syntex S.A. (Madrid, Spain; study I) and by Syntex
S.A. (Mexico City, Mexico; study II). Bayer (Madrid, Spain) and
Novartis (Mexico City, Mexico) kindly supplied ibuprofen and so-
dium diclofenac (used as internal standards), respectively.
Lipopolysaccharide from Escherichia coli, serotype 0111:B4 was
purchased from Sigma (Barcelona, Spain). Carrageenin was pur-
chased from Sigma (St. Louis, MO). All reagents and solvents used
were purchased from commercial sources and were of analytical
grade.
Animals
Male Wistar rats, weighing 180 to 270 g were used in studies I and
II. Animals were kept under laboratory standard conditions on a
12-h light/dark cycle with light from 8:00 AM to 8:00 PM, in a
temperature (22°C)-controlled room, and were acclimatized for a
minimum of 2 days before experiments were performed. They were
housed in individual cages after the surgical procedures, with free
access to water. Food was withheld for 12 h before the start of
experiments. The protocols of the studies were approved by the
Committee of Animal Experimentation of the University of Navarra
and of the Centro de Investigacio´n y Estudios Avanzados del Insti-
tuto Polite´cnico Nacional (Mexico City), respectively.
Surgical Procedure
The day before the experiments, rats were anesthetized i.p. with
100 mg/kg ketamine (Ketolar; Parke-Davis, Madrid, Spain) and 15
mg/kg xylazine (Rompun; Bayer, Mexico City, Mexico) for studies I
and II, respectively.
In study I, two polyethylene (0.5 mm i.d., 11-cm-long; 0.3 mm i.d.,
21-cm-long; Vygon, Ecouen, France) catheters were implanted in the
right femoral artery and in the left jugular vein for blood sampling
and drug administration, respectively. Rats in study II were surgi-
cally implanted with polyethylene catheters into the caudal artery as
described previously (Granados-Soto et al., 1995). All catheters were
filled with heparinized saline solution (20 IU/ml) to prevent clotting.
Experimental Protocol
Study I. Figure 1, left, represents the dosing and pk and pd data
collection schedules used for study I.
Induction of fever and pd data measurements. Animals (n 5 30)
were randomly divided into five groups. Sterile saline solution (0.5
ml) containing 0.1 mg/kg lps was given i.p. to groups II to V, whereas
the group I (baseline) only received 0.5 ml of sterile saline solution
i.p. The lps solution was prepared at the beginning of the experiment
and was injected at 37°C to animals. Ta was monitored in the rectum
once every 30 min for 11 h just before and after the injection of the
lps with a rectal thermometer (Panlab model 0331; Barcelona,
Spain).
Drug administration and pk data collection. Naproxen was admin-
istered as an aqueous solution neutralized with NaOH and filled up
to the administered volume with a phosphate-buffered solution (Lau-
Fig. 1. Experimental design carried out in the current study for the analysis of the antipyretic (left) and anti-inflammatory (right) effects.
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roba et al., 1986). The pH of the administered solution was 7.6 and
the maximum infused volume was 0.7 ml.
Naproxen was given as different i.v. infusions after lps injection on
the basis of the following schedule: group III, a total dose of 7 mg/kg
was infused over 15 min, 5.5 h after lps injection; group IV, a total
dose of 7 mg/kg was infused over 30 min, 5.5 h after lps injection;
group V, a total dose of 7 mg/kg was infused in 15 min, 3 h after lps
injection. Group II (control) received in 15 min an i.v. infusion with
the same volume of saline that was given to group III.
Arterial blood samples (n 5 13) of 100 to 200 ml were withdrawn
during and after the drug or saline infusions. Sampling was carried
out to define the plasma drug concentrations versus time profiles
(groups III to V), or to explore the influence of blood sampling on
rectal Ta (group II). Blood samples were transferred to heparinized
tubes and were immediately centrifuged to separate the plasma,
which was frozen and kept at 220°C until analysis was performed.
The same volume of extracted blood was reconstituted with physio-
logical saline solution.
Drug analysis. Briefly, plasma samples (50–100 ml) were spiked
with 50 ml of methanol containing the internal standard (ibuprofen)
at a concentration of 200 mg/ml followed by acidification with 0.3 ml
of 2 N HCl. After the double addition of 2 ml of tert-butylmethylether,
samples were shaken on a vortex mixer for 1 min and centrifuged for
5 min at 3500 rpm. The organic phase was transferred to a 10-ml
tube and evaporated to dryness at vacuum in a vortex evaporator at
40°C. The dried residues were reconstituted with 500 ml of mobile
phase and 100 ml were injected into the chromatographic system.
This consisted of a Hewlett Packard high performance liquid chro-
matograph HP 1100 equipped with a quaternary pump, an autosam-
pler, and a diode-array detector set at 229 nm.
Separations were achieved on a reversed phase Kromasil 100 C18
column (250 3 4 mm i.d., 5-mm particle size) provided by Tecknok-
roma (Barcelona, Spain). The mobile phase was acetonitrile in 0.01
M phosphate buffer adjusted to pH 1.5 (60:40 v/v). The mobile phase
was delivered at a constant flow rate of 1 ml/min and the chromato-
graph was carried out at 40°C. The signal showed linearity over the
range 0.05 to 75 mg/ml with intra- and interday coefficients of vari-
ation of the assay of 3.36 and 3.86%, respectively.
Study II. Figure 1, right, depicts the dosing and pk and pd data
collection schedules used for study II.
Induction of paw inflammation and pd data collection. Animals
(n 5 24) were randomly allocated into four groups. To induce inflam-
mation all animals were injected s.c. into the right hind paw with 0.1
ml of a 1% carrageenin suspension in 0.9% saline. Induced inflam-
mation was measured by plethysmography as it has been described
before (Winter et al., 1962). Paw swelling was determined once just
before and during the following 6 h to carrageenin and drug admin-
istration.
Drug administration and pk data collection. Animals were treated
orally with naproxen 1.7 mg/kg (group II), 3.2 mg/kg (group III), and
10 mg/kg (group IV), suspended in 0.5% carboxymethyl cellulose
solution. The drug was given in a volume equal to 4 ml/kg and was
simultaneously administered with the injection of carrageenin.
Group I (control) received only carrageenin and blood samples were
taken to study the influence of sampling on the time course of paw
swelling.
Arterial blood samples (n 5 7) of 200 ml were withdrawn at
selected times for 6 h. Plasma was obtained by centrifugation, frozen,
and kept at 220°C until analysis. The same volume of withdrawn
blood was replaced with sterile saline.
Drug analysis. Measurements of naproxen in plasma were carried
out using the method previously described by Borgå and Borgå
(1997) with some modifications. Briefly, plasma samples (10 ml) were
spiked with 20 ml of methanol containing the internal standard
(diclofenac) at a concentration of 50 mg/ml. This mixture was diluted
to 500 ml with phosphate buffer (pH 5 7) and stirred until homoge-
nization. Then, 20 ml was injected into the chromatograph.
The chromatographic system consisted of a Waters 510 pump
(Waters Associates, Milford, MA), a Rheodyne 7725i injector with a
20-ml loop (Cotati, CA), and a Waters 484 variable wavelength de-
tector set up at 231 nm. Separations were achieved on a Symmetry
C18 150 3 3.9-mm (i.d.) column, 4-mm particle size (Waters Associ-
ates) using a mixture of 1 mM phosphoric acid and acetonitrile (62:38
v/v) as the mobile phase. The mobile phase was delivered at a
constant flow rate of 0.8 ml/min and chromatography was carried out
at room temperature. The signal showed linearity over the range 0.1
to 50 mg/ml. The intra- and interday coefficients of variation of the
assay were 3.14 and 4.94%, respectively.
Data Analysis
The time course of the drug concentration and antipyretic/anti-
inflammatory effect were analyzed with a population approach using
the first order method implemented in NONMEM (version V) soft-
ware (Beal and Sheiner, 1992). This approach makes it possible to
simultaneously fit data from all individuals, describing both mean
population tendencies and individual profiles, and provides esti-
mates for the interindividual variability and residual (intraindi-
vidual) error. Data for study I and II were analyzed separately.
Interanimal variability was fitted using exponential models. Re-
sidual variability was modeled by using a constant-coefficient vari-
ation model for plasma drug concentrations, and an additive model
for effect measurements.
Model selection was based on the exploratory analysis of goodness-
of-fit plots performed with Xpose package (Jonsson and Karlsson,
1999), the estimates of the parameters, and their confidence inter-
vals. The minimum value of the objective function provided by
NONMEM was also used as a criterion for model selection. The
difference in the objective function between two hierarchical models
is approximately chi square distributed; p , 0.05 was used as the
level of significance. Results from data analysis are presented as
estimated values and their relative standard error. Estimates of the
interanimal and residual variability are expressed as coefficients of
variation (%).
Pharmacokinetic Models. Naproxen disposition properties
were characterized by compartmental models. In the case of study II,
different absorption models were tested: first order, zero order, and
Michaelis-Menten absorption models; the presence of a lag time was
also explored.
Pharmacodynamic Models. Figure 2 shows the models fitted to
the data for studies I and II.
Study I: antipyretic effect. After injection of lps control group
showed a time-varying response, which was modeled using the fol-
lowing model:
dR
dt 5 Ksyn 1 IR(t) 2 Kout 3 R (1)
where dR/dt represents the rate of change in response (Ta); Ksyn is
the zero order rate constant of response formation and Kout is the
first order rate constant of response degradation. IR(t), the input
rate function representing the increase in the formation of fever
mediators accounting for the temporal increase in response, was
modeled nonparametrically using a linear spline. A linear spline is
characterized by a number of real numbers called breakpoints and a
number of polynomials, which simply join at the breakpoints (De-
Boor, 1978). In this study the breakpoints were located at the times
of observations. The number and location of the breakpoints were
selected as a part of the model-building process. The heights of the
spline at each of the breakpoints were parameters to be also esti-
mated during the model-building process together with the rest of
the pharmacodynamic parameters, and were constrained to be non-
negative.
Drug effect (DRUG) was incorporated to the previous equation as
follows:
dR
dt 5 Ksyn 1 IR(t) 3 ~1 2 DRUG! 2 Kout 3 R (2)
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This model assumes that naproxen exerts its action by the inhi-
bition of the lps-induced synthesis of fever mediators. Different mod-
els were tested for DRUG: lineal, Emax, and sigmoidal Emax models.
Study II: anti-inflammatory effect. Although previous equations
were suitable for describing Ta data when applied to inflammation
data, the model predictions obtained were not satisfactory. Thus, a
more complex model was built to account for the delayed increase in
inflammation in naproxen-treated groups in comparison with con-
trol. This model assumes that 1) carrageenin injection elicits a tran-
sient formation of inflammatory mediators (M), which is described by
the input rate function IR(t) (see above); 2) the mediator-induced
inflammatory response is governed by a first order rate constant
(KIN), which can be inhibited by naproxen in plasma; and 3) in
absence of carrageenin and/or drug in the body, a certain degree of
inflammation (baseline level) is maintained by the balance between
the production (represented by the zero order rate constant, Ksyn)
and the degradation (represented by the first order rate constant,
Kout) of inflammatory response. The model is represented by the
following set of differential equations:
dM
dt 5 IR(t) 2 KIN 3 ~1 2 DRUG! 3 M (3)
dR
dt 5 KIN 3 ~1 2 DRUG! 3 M 1 Ksyn 2 Kout 3 R (4)
where dM/dt represents the rate of change of inflammatory media-
tors, dR/dt is the rate of change of inflammatory response, and
DRUG is the effect of naproxen on the system. Different models were
tested for DRUG: lineal, Emax, and sigmoidal Emax models.
Statistical Analysis. Results from studies I and II after injection
of lps or carrageenin are showed as mean data with their correspond-
ing standard deviations. Within each study, comparisons of the ob-
served responses between the different groups were made by one-
way ANOVA followed by a Tukey’s posteriori test. Statistical
significance was set at p , 0.05.
Results
Study I
Pharmacokinetics. A three-compartment model was
used to describe the kinetics of naproxen in plasma. Esti-
mates of the typical pk parameters and their values of inte-
ranimal variability are listed in Table 1. Mean observed and
typical model-predicted plasma concentration versus time
profiles are shown in Fig. 3. Mean observed plasma concen-
trations at the time the infusions were stopped were 46.22 6
2.11, 55.45 6 6.39, and 52.85 6 2.72 mg/ml for the 30- and
15-min infusions, respectively.
Pharmacodynamics. Figure 4 shows the mean observed
Ta versus time profiles for all groups injected with lps in
study I. Baseline group showed a constant basal body Ta over
a 12-h period with a mean 6 S.D. value of 37.2 6 0.06°C.
Basal Ta recorded at the time of lps injection did not differ
statistically among groups I to V (p . 0.05). In addition, at
the times Ta were recorded between lps injection and the
start of the drug infusions no statistical differences in Ta (p .
0.05) were found among groups II to V. A mean maximal
increase in body Ta of 38.27 6 0.15°C located at 5.3 6 0.4 h
after lps injection was found for group II; Ta then returned
gradually to baseline; 11 h after lps injection mean observed
Ta was 37.92 6 0.33°C. Mean times to baseline were 8 6 1.5,
11 6 1, and 4.5 6 1.6 h for groups III, IV, and V, respectively.
The onset of the antipyretic effects was fast in the three
groups. However, Ta returned to baseline with a 2- to 3-h
delay with respect to time to peak plasma concentrations,
indicating that observed effects and plasma drug concentra-
tions could not be related directly.
Pharmacokinetic/Pharmacodynamic Modeling Re-
sults. Figure 4 shows the typical model-predicted time
course of Ta in all groups on the basis of the model described
in Fig. 2 (top) and by eqs. 1 and 2. It can be observed that
model predictions for groups III and IV are almost superim-
posable; the fact that plasma drug concentrations for both
groups at early times after the end of the infusion were 9 to
Fig. 2. Schematic representation of the pharmacodynamic model used to
describe the data for study I (top) and study II (bottom). IR(t), input rate
function of fever or inflammation mediators; KIN, first order rate constant
of release of inflammation mediators into the inflammation compart-
ment; Ksyn, zero order rate constant of formation of basal fever or inflam-
matory response; Kout, first order rate constant of degradation of fever or
inflammatory response.
TABLE 1
Pharmacokinetic parameter estimates of naproxen given in 15- or 30-
min i.v. infusions of 7 mg/kg to rats
Estimates of interanimal (IAV) variability are expressed as coefficients of variation
(%). Precision of the estimates is expressed as relative standard error in parentheses.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate IAV
V1 (ml/kg) 45.2 (0.097) 20 (0.45)
CL (ml/h/kg) 32 (0.039) 16 (0.37)
V2 (ml/kg) 73.6 (0.09) N.E.
V3 (ml/kg) 60.8 (0.088) 32 (0.73)
CLD1 (ml/h/kg) 980 (0.15) N.E.
CLD2 (ml/h/kg) 108.8 (0.24) N.E.
V1, initial volume of distribution; CL, total plasma clearance; V2 and V3, shallow
and deep compartment volumes of distribution, respectively; CLD1 and CLD2, inter-
compartmental clearances between plasma and shallow and between plasma and
deep compartment, respectively; N.E., not estimated in the model.
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11 times higher than the estimated value of IC50, together
with the high interindividual variability, could explain this
issue. Figure 5 shows in solid line the selected shape for the
linear spline representing the input rate of fever mediators
responsible for the temporal increase in body Ta. The break-
points were selected at times 0, 2, 6, and 11 h after lps
injection. It can be observed that IR(t) has a value different
from zero at t 5 0. This result should be interpreted as an
almost instantaneous increase in the synthesis of fever me-
diators after the lps injection. The effect of naproxen plasma
concentrations on the inhibition of IR(t) was described by an
inhibitory Emax model. Table 2 lists the estimates of the
parameters of the linear spline and pd parameters and their
estimates of interanimal variability; all parameters were
estimated with an adequate precision. During the model
building process Emax was estimated close to 1; for that
reason, its value was fixed (Table 2). At times before lps
injection dT/dt 5 0 5 Ksyn 2 Kout z E0, where E0 is the basal
Ta; then Ksyn 5 Kout z E0. The typical value of Ksyn computed
using the estimates of Kout and E0 was 29.76°C/h.
Study II
Pharmacokinetics. A one-compartment model was
enough to describe the disposition of naproxen in plasma
when the drug was given orally. The typical values of the
estimates (and their associated interanimal variability) for
plasma clearance (CL) and apparent volume of distribution
(V), which in the case of the three-compartment model is the
sum of the initial volume of distribution, and shallow and
deep compartment volumes of distribution (V1, V2, and V3,
respectively; Table 1), were very similar between the two
studies. Table 3 lists the typical pk parameters and their
values of interanimal variability for naproxen obtained from
study II; the mean observed and typical model-predicted
plasma naproxen concentration versus time profiles are
shown in Fig. 6. Relative bioavailability for the group receiv-
ing the lowest dose was fixed to 1, and bioavailability for
groups receiving 3.2 and 10 mg/kg were estimated with a
value significantly lower than 1 (p , 0.05); a 25% reduction
of bioavailability was found in the highest dose group. Mean
maximum plasma concentrations of naproxen were observed
20 min after drug administration in all groups and with
Fig. 3. Time course of plasma concentrations of naproxen in study I.
Symbols represent mean observed data, lines represent typical model
predictions, and vertical lines represent standard deviations.
Fig. 4. Time course of rectal Ta after lps injection and naproxen admin-
istration (symbols, mean observations; lines, typical model predictions).
Vertical lines represent standard deviations.
Fig. 5. Profiles of the selected input rate functions of fever (solid line) and
inflammation (dashed line) mediators.
TABLE 2
Pharmacodynamic results obtained from the
pharmacokinetic/pharmacodynamic modeling of the antipyretic
effect of naproxen in the rat
Estimates of interanimal (IAV) variability are expressed as coefficients of variation
(%). Precision of the estimates is expressed as relative standard error in parentheses.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate IAV
P(0) (°C/h) 0.016 (0.20) N.E.
P(2) (°C/h) 0.014 (0.14) N.E.
P(6) (°C/h) 0.028 (0.13) N.E.
P(11) (°C/h) 0.0065 (0.31) N.E.
Kout (1/h) 0.798 (0.13) 39 (0.42)
E0 (°C) 37.3 (0.006) 0.7 (0.24)
IC50 (mg/ml) 4.24 (0.22) 327 (0.42)
P(0), P(2), P(6), and P(11), heights of the linear spline located at the 0-, 2-, 6-, and
11-h breakpoints, respectively. P(0), P(2), P(6), and P(11) determine the shape of IR(t)
(see Fig. 5); Kout, first order rate constant of degradation of T
a; E0, baseline T
a; IC50,
naproxen plasma concentration eliciting half of maximum IR(t) inhibition; N.E., not
estimated in the model.
TABLE 3
Pharmacokinetic parameter estimates of naproxen given orally at doses
of 1.7, 3.2, and 10 mg/kg to rats
Estimates of interanimal (IAV) variability are expressed as coefficients of variation
(%). Precision of the estimates is expressed as relative standard error in parentheses.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate IAV
V (ml/kg) 164 (0.16) 16 (0.34)
CL (ml/h/kg) 33.6 (0.21) 20 (0.44)
KA (1/h) 14.82 (0.08) 50 (0.48)
F (1.7 mg/kg) 1 FIX N.E.
F (3.2 mg/kg) 0.8 (0.9) N.E.
F (10 mg/kg) 0.77 (0.1) N.E.
V, volume of distribution; CL, total plasma clearance; KA, first order rate con-
stant of absorption; F, bioavailability; N.E., not estimated in the model; FIX, fixed
parameter.
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values of 9.1 6 0.8, 14.4 6 0.7, and 39.3 6 3.1 mg/ml for the
1.7-, 3.2-, and 10-mg/kg dose groups, respectively.
Pharmacodynamics. Figure 7 shows the mean observed
paw swelling versus time profiles. Mean basal swelling val-
ues did not differ significantly between groups (p . 0.05). A
maximum paw swelling of 46.55 6 2, 48.7 6 2.5, 44.5 6 2.3,
and 40.5 6 2.4 ml was found for groups I-IV, respectively.
These maximums were observed at 3.3 6 0.8, 4.8 6 0.26,
5.5 6 0.55, and 5.9 6 0.2 h, after the injection of carrageenin,
respectively. No statistical differences were found between
groups at the end of the experiment (p . 0.05). In groups III
and IV paw swelling remained at basal levels for 2 6 0.89 and
3 6 0.52 h after the start of the experiment, respectively.
Pharmacokinetic/Pharmacodynamic Modeling Re-
sults. Figure 7 shows the typical model predicted time course
of the inflammation response using the model described by
eqs. 3 and 4 and Fig. 2 (bottom). In this case the shape of the
selected linear spline was similar to the profile of a constant
input rate function that could be characterized by K0 (zero
order rate constant) and Tsyn, (duration of the input rate
function). Figure 5 shows in dashed line the profile of the
input rate function of inflammation mediators. The effect of
naproxen was described by an inhibitory sigmoidal Emax
model. The estimates of the pd parameters and their esti-
mates of interindividual variability are listed in Table 4.
Emax was also fixed to 1, since in the case of groups III and IV,
plasma drug concentrations were able to block completely the
onset of inflammatory response for 2 and 3 h, respectively.
Ksyn, computed as in study I, had a value of 19.2 ml/h.
Discussion
Study I
Pharmacokinetics. The estimates of V1 (45.2 ml/kg) and
CL (32 ml/h/kg) obtained from the fit of i.v. data were in
agreement with those published previously in rats (Lauroba
et al., 1986; Castan˜eda-Herna´ndez et al., 1995), and also in
humans where the estimates of CL and V reported by Davies
and Skjodt (2000) were 42 ml/h/kg and 100 ml/kg, respec-
tively. The fact that a three-compartmental model was se-
lected, when, in general, most authors have used the two-
compartmental model to describe the kinetics of naproxen in
plasma, could be related to the i.v. infusion design used here
and the extensive sampling.
Pharmacodynamics. To describe the time course of the
antipyretic effects of naproxen, estimating at the same time
reliable pd parameters, we induced fever experimentally by
i.p. injection of lps (0.1 mg/kg) from E. coli (Wachulec et al.,
1997). Several authors have used the same design to study
the physiological factors influencing fever response (Cao et
al., 1997; Matsumura et al., 1998; Molina-Holgado et al.,
1998). Our results were very similar to those obtained by
Wachulec et al. (1997), using rats of the same strain, sex, and
age, and receiving the same dose of lps; the authors found a
maximum mean increase of 38.6°C located 6 h after lps
injection. In our study those values were 38.3°C and 5.5 h,
respectively. At the time the experiment ended, 11 h after lps
injection, mean observed Ta was 37.92°C, a reduction of al-
most 40% on the maximum achieved.
On the basis of observed response versus time profiles, a
suitable model should take into consideration the following
issues: 1) no circadian variation in Ta; 2) the transient in-
crease in Ta, after lps injection, is elicited by an increase in
the synthesis of PGE2; 3) naproxen before lps injection does
not elicit any change in Ta; 4) in adequate concentrations,
naproxen can inhibit the transient increase in Ta; and 5)
there is no evidence of a rebound effect.
In our proposed model, the equation dT/dt 5 Ksyn 2 Kout z
Ta predicted a time invariant baseline Ta. The estimate of
Kout (0.798 1/h) was similar to the 0.89 and 1.17 1/h estimates
Fig. 6. Time course of plasma concentrations of naproxen in study II.
Symbols represent mean observed data, lines represent typical model
predictions, and vertical lines represent standard deviations.
Fig. 7. Time course of inflammation after carrageenin injection and
naproxen administration (symbols, mean observations; lines, typical
model predictions). Vertical lines represent standard deviations.
TABLE 4
Pharmacodynamic results obtained from the
pharmacokinetic/pharmacodynamic modeling of the anti-inflammatory
effect of naproxen in the rat
Estimates of interanimal (IAV) variability are expressed as coefficients of variation
(%). Precision of the estimates is expressed as relative standard error in parentheses.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate IAV
Kout (1/h) 0.6 (0.45) 47 (0.35)
KIN (1/h) 1.05 (0.4) N.E.
K0 (ml/h) 0.35 (0.4) N.E.
Tsyn (h) 4.26 (0.07) N.E.
E0 (ml) 32 (0.01) 36 (0.53)
IC50 (mg/ml) 4.13 (0.27) 7 (0.31)
g 1.5 (0.11) N.E.
Kout, first order rate constant of degradation of inflammatory response; KIN, first
order rate constant of release of inflammation mediators into the inflammation
compartment; K0, zero order rate constant rate of synthesis of inflammation medi-
ators; Tsyn, duration of inflammation mediator synthesis; E0, baseline paw swelling;
IC50, naproxen plasma concentration eliciting half of maximum KIN inhibition; g,
slope parameter; N.E., not estimated in the model.
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given by Garg and Jusko (1994) and Troco´niz et al. (2000),
respectively, during the pk/pd modeling of the antipyretic
effects of racemic ibuprofen in children. Since there was a
lack of information regarding the time course of the increas-
ing formation of PGE2, that profile was estimated by the
model using a linear spline constrained to be non-negative.
Figure 5 shows that in fact the value of the input rate func-
tion, called IR(t), is not constant and once it reaches a peak at
6 h after lps injection it declines linearly. At the end of the
experiment (11 h after lps injection) the value of the input
rate function was significantly different from zero (p , 0.05).
Splines have been used for exploratory analysis and model-
ing purposes (Gries et al., 1999; Fattinger et al., 2000) when
there was not an a priori, physiological basis on which to
choose a specific form; in our case a time invariant or a
periodic input rate constant of synthesis of PGE2. Allowing
IR(t) to be non-negative and independent of Ksyn, it was
possible to account for points 3 and 5 (see above). The most
likely mechanism of action of the NSAIDS, the inhibition of
the synthesis of PGE2 (Zhang et al., 1997), is represented by
an Emax model decreasing IR(t). The estimate of IC50 (4.24
mg/ml) is close to the IC50 values of 10.1 and 6.18 mg/ml given
by Garg and Jusko (1994) and Troco´niz et al. (2000), respec-
tively.
Study II
Pharmacokinetics. When the area under plasma drug
concentrations corrected by mean dose versus time curves
(AUCdose) was computed, the value of AUCdose obtained from
the 1.7-mg/kg oral dose was comparable with the value of
AUCdose from study I (29 and 30 mg z h/ml, respectively), but
AUCdose from the 3.2- and 10-mg/kg oral dose groups tended
to be lower (23 and 22 mg z h/ml, respectively). On the basis
of these preliminary results we assumed complete F for the
lowest oral dose group and allowed the estimation of F for the
higher oral dose groups. Previous studies have also shown
that naproxen has a high but not complete F (Lauroba et al.,
1986). The reason for a decrease in F when the dose is
increased is not clear but it could be the case that there is a
limited time for the drug to be absorbed in the gut, and that
time limitation could cause the fraction of dose absorbed to be
lower for the highest doses.
Pharmacodynamics. The carrageenin-induced edema
model has long been used to evaluate the anti-inflammatory
activity of NSAIDs (Seibert et al., 1994; Smith et al., 1998).
The time profile of the paw swelling found for the baseline
group in the current study was very similar to the one pub-
lished by Castan˜eda-Herna´ndez et al. (1995), using rats of
the same strain, sex, and age, receiving the same dose of
carrageenin. They found a maximum paw swelling increase
of 38% located after 4 h after carrageenin injection, whereas
we observed corresponding values of 46.2% and 4 h, respec-
tively. By the time the experiment was stopped, average paw
volume had been declined to 34.3% in our study and 35% in
Castan˜eda-Herna´ndez et al. (1995) study. On the other hand,
Davies and Skjodt (2000) indicated that plasma naproxen
concentrations of 50 mg/ml or doses between 3.5 and 22 mg/kg
were needed to achieve an adequate anti-inflammatory re-
sponse in humans, which are values very close to the ones
reported in the current study.
To estimate pd parameters of naproxen “in vivo” we pro-
posed several models to fit the experimental data. Previous
studies had shown that COX-2 expression was experimen-
tally induced in the footpad by carrageenin and that the
elicited inflammation could be blocked by the administration
of a selective COX-2 inhibitor (Seibert et al., 1994). These
results support the hypothesis that COX-2-derived PGE2
plays a crucial role in the initiation and maintenance of
inflammatory response. On the basis of these considerations,
a first attempt was to propose a model similar to the one used
during study I to describe antipyresis. However, the only
group that could be adequately described was the control
group. The reason for the lack of fit of a simple indirect
response model is due to the fact that the effect of naproxen
seems to be more related to a delay in the onset of the
inflammatory response rather than to a decrease in the ex-
tent of inflammation. Indeed, it appears that naproxen acted
at the level of blocking the pass from the mediator compart-
ment to the inflammatory response compartment, i.e., acting
on the release more than synthesis of mediators.
The model describing the time course of inflammatory re-
sponse in the control group has a similar structure to the one
published recently by Gozzi et al. (1999) to account for the
transient increase in plasma concentration of lps-induced
tumor necrosis factor-a in the mouse. However, when this
model was used to fit our data no satisfactory predictions
were obtained. Thus, we adapted the model in such a manner
that the drug acts through the inhibition of KIN instead of
through the inhibition of K0 as in Gozzi’s study. Our pk/pd
model assumes that inflammation mediators increase their
production for a certain time after carrageenin injection, and
that the increase in the inflammatory response depends on
the amount of such mediators. Indeed, Fitzgerald et al.
(1981) described a first order rate for the release of a pros-
taglandin in humans, whereas the period of the observed
increase in COX-2 mRNA in vivo, as well as the proinflam-
matory PG formation, reported by Seibert et al. (1994) and
Smith et al. (1998) highly correlates with the duration of
inflammatory mediator synthesis (Tsyn) estimated by the
model. It should be noted that the shape of IR(t) selected in
the inflammation study differs from the shape obtained dur-
ing the analysis of the antipyretic effects (Fig. 5), however,
the estimates of IC50 for the antipyretic and anti-inflamma-
tory effects, 4.24 and 4.13 mg/ml, respectively, are very sim-
ilar, and resemble the value for in vitro inhibition of COX-1/
COX-2 for the NSAID (2.2/1.3 mg/ml; Mitchell et al., 1993).
It is important to underline that our model was unable to
describe the first peak in paw swelling observed at 0 to 15
min. However, the edema produced by this period might be
the result of local bradykinin production insensitive to the
action of anti-inflammatory NSAIDs as described Seibert et
al. (1994). Therefore, this lack of predictability of the model
might be considered irrelevant to characterize the pd of
naproxen.
In summary, different pk/pd models were proposed to de-
scribe the antipyretic and anti-inflammatory effects of
naproxen in the rat, but can also be generalized to a class of
models dealing with complex interactions between time-vari-
ant disease-induced response and drug effects. Antipyresis
could be described using a standard indirect response model,
but anti-inflammatory response required a more complex
model, including an extra compartment dealing with the
time course of the inflammatory mediators. These differences
may be related to the level of interaction of naproxen with
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cyclooxygenase, i.e., if PGE2 produced in brain is the main
factor responsible of lps-induced fever, the inhibition of its
biosynthesis would be the limiting step for the antipyretic
activity of naproxen. On the other hand, inflammation ap-
pears to be a more complex process where edema formation
involves vascular events, local and recruited cell activation,
production of mediators, and finally synthesis of proinflam-
matory prostanoids. Thus, there may be more than one target
in that cascade of events, which explain the anti-inflamma-
tory effect of naproxen.
Acknowledgments
We thank Drs. Marta Valle and Davide Verotta for help in coding
linear splines within the NONMEM program. The generous gift of
naproxen by Syntex is greatly appreciated.
References
Beal SL and Sheiner LB (1992) NONMEM Users Guides. NONMEM Project Group,
University of California at San Francisco, San Francisco, CA.
Borgå O and Borgå B (1997) Serum protein binding of nonsteroidal anti-
inflammatory drugs: A comparative study. J Pharmacokinet Biopharm 25:63–77.
Brown RD, Kearns GL and Wilson JT (1998) Integrated pharmacokinetic-
pharmacodynamic model for acetaminophen, ibuprofen and placebo antipyresis in
children. J Pharmacokinet Biopharm 26:559–579.
Cao C, Matsumura K, Yamagata K and Watanabe Y (1997) Involvement of cycloox-
ygenase-2 in lps-induced fever and regulation of its mRNA by lps in the rat brain.
Am J Physiol 272:R1712–R1725.
Castan˜eda-Herna´ndez G, Favari L and Hoyo-Vadillo C (1995) Relationship between
naproxen plasma concentration and its anti-inflammatory effect in experimental
hepatitis. Arzneim-Forsch/Drug Res 45:585–589.
Coderre TJ, Gonzales R, Goldyne ME, West J and Levine JD (1990) Noxious stim-
ulus-induced increase in spinal prostaglandin E2 is noradrenergic terminal de-
pendent. Neurosci Lett 115:253–258.
Davies NM and Anderson KE (1997) Clinical pharmacokinetics of naproxen. Clin
Pharmacokinet 32:268–293.
Davies NM and Skjodt NM (2000) Choosing the right non-steroidal antiinflamma-
tory drug for the right patient. A pharmacokinetic approach. Clin Pharmacokinet
38:377–392.
DeBoor C (1978) A Practical Guide to Splines. Springer Verlag, New York.
Di Rosa M, Giroud JP and Willoughby DA (1971) Studies of the mediators of the
acute inflammatory response induced in rats in different sites by carrageenan and
turpentine. J Pathol 104:15–29.
Ehrich EN, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A,
Wittreich J, Seibold JR, De Schepper P, et al. (1999) Characterization of rofecoxib
as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the
dental pain model. Clin Pharmacol Ther 65:336–347.
Fattinger K, Benowitz NL, Jones RT and Verotta D (2000) Nasal mucosal versus
gastrointestinal absorption of nasally administered cocaine. Eur J Clin Pharmacol
56:305–310.
Fitzgerald GA, Brash AR, Falardeau P and Oates JA (1981) Estimated rate of
prostacyclin secretion into the circulation of normal man. J Clin Invest 68:1272–
1275.
Garg V and Jusko WJ (1994) Pharmacodynamic modeling of nonsteroidal anti-
inflammatory drugs: Antipyretic effect of ibuprofen. Clin Pharmacol Ther 55:87–
88.
Gozzi P, Pahlman I, Palmer L, Gronberg A and Persson S (1999) Pharmacokinetic-
pharmacodynamic modeling of the immunomodulating agent susalimod and ex-
perimentally induced tumor necrosis factor-a levels in the mouse. J Pharmacol
Exp Ther 291:199–203.
Granados-Soto V, Lo´pez-Mun˜oz FJ, Hong E and Flores-Murrieta FJ (1995) Relation-
ship between pharmacokinetics and the analgesic effect of ketorolac in the rat.
J Pharmacol Exp Ther 272:352–356.
Gries JM, Munafo A, Porchet HC and Verotta D (1999) Down-regulation models and
modelling of testosterone production induced by recombinant human choriogona-
dotropin. J Pharmacol Exp Ther 289:371–377.
Jonsson EN and Karlsson MO (1999) Xpose: An S-PLUS based population pharma-
cokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods
Programs Biomed 58:51–64.
Kelley MT, Walson PD, Edge JH, Cox S and Mortensen ME (1992) Pharmacokinetics
and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile chil-
dren. Clin Pharmacol Ther 52:181–189.
Kluger MJ (1991) Fever: Role of pyrogens and cryogens. Physiol Rev 71:93–127.
Landoni MF, Comas W, Mucci N, Anglarilli G, Bidal D and Lees P (1999) Enantio-
specific pharmacokinetics and pharmacodynamics of ketoprofen in sheep. J Vet
Pharmacol Ther 22:349–359.
Landoni MF and Lees P (1996) Pharmacokinetics and pharmacodynamics of keto-
profen enantiomers in the horse. J Vet Pharmacol Ther 19:466–474.
Langenbach R, Loftin C, Lee C and Tiano H (1999) Cyclooxygenase knockout mice.
Biochem Pharmacol 58:1237–1246.
Lauroba J, Domenech J, Moreno J and Pla-Delfina JM (1986) Relationships between
biophasic disposition and pharmacokinetic behavior in nonsteroid antiinflamma-
tory drugs. Arzneim-Forsch/Drug Res 36:710–714.
Matsumura K, Cao C, Ozaki M, Morii H, Nakadate K and Watanabe Y (1998) Brain
endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fe-
ver: Light and electron microscopic immunocytochemical studies. J Neurosci 15:
6279–6289.
Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ and Vane JR (1993)
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive
and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697.
Molina-Holgado F, Borrell J and Guaza C (1998) Effect of endotoxin and interleukin-
1beta on corticotropin-releasing-factor and prostaglandin release by rat brainstem
slices. J Neuroendocrinol 10:429–436.
Oka K, Oka T and Hori T (1997) Prostaglandin E2 may induce hyperthermia through
EP1 receptor in the anterior wall of the third ventricle and neighboring preoptic
regions. Brain Res 767:92–99.
Ruwe WD, Naylor AM and Veale WL (1985) Perfusion of vasopressin within the rat
brain suppresses prostaglandin E-hyperthermia. Brain Res 338:219–224.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L and Isakson
PC (1994) Pharmacological and biochemical demonstration of the role of cycloox-
ygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013–12017.
Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ,
Masferrer JL, Seibert K and Isakson PC (1998) Pharmacological analysis of
cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313–13318.
Troco´niz IF, Armenteros S, Planelles MV, Benı´tez J, Calvo R and Domı´nguez R
(2000) Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of
two oral formulations of ibuprofen. Clin Pharmacokinet 38:505–518.
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of
aspirin-like drugs. Nat New Biol 231:232–235.
Vane JR and Botting RM (1994) Biological properties of cyclooxygenases products, in
Lipid Mediators (Cunningham FM ed) pp 61–97, Academic Press Limited, New
York.
Wachulec M, Peloso E and Satinoff E (1997) Individual differences in response to lps
and psychological stress in aged rats. Am J Physiol 272:R1252–R1257.
Winter CA, Risley GA and Nuss GW (1962) Carrageenin-induced edema in hind paw
of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med
648:80–86.
Yirmiya R, Rosen H, Donchin O and Ovadia H (1994) Behavioral effects of lipopoly-
saccharide in rats: Involvement of endogenous opioids. Brain Res 648:80–86.
Zhang Y, Shaffer A, Portanova J, Seibert K and Isakson PC (1997) Inhibition of
cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin
E2 production. J Pharmacol Exp Ther 283:1069–1075.
Send reprint requests to: In˜aki F. Troco´niz, Ph.D., Department of Phar-
macy and Pharmaceutical Technology, Faculty of Pharmacy, University of
Navarra, Pamplona 31080, Spain. E-mail: itroconiz@unav.es
pd/pk Model for Naproxen 205
 at Universidad de Navarra-Servicio de Bibliotecas on April 13, 2012
jpet.aspetjournals.org
D
ow
nloaded from
 
